Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Insmed up over 100% in three months

|Includes: Insmed, Inc. (INSM)

The market is finally realizing the value of this company.  Congratulations to those of you who held on, and now have at least a double or a triple.  As I stated in my previous articles, this company has executed as planned, and should continue to do so.

INSM provides an excellent lesson in market mispricing.  Just three months ago shares were trading at $4.69, grossly undervalued.  But the market believed that was the correct price.  At times like that it's difficult to believe that the market is wrong, but it's good to remember that the market can be grossly wrong, providing us with tremendous opportunity.

There have been two websites posting information about J.P. Morgan issuing a $25 price target for INSM.  One of the links now generates an error message, so at this point, JP Morgan's rating is unsubstantiated.  I wish to thank all Seeking Alpha readers for bringing this to my attention.